SCHEMBL8507258

SCHEMBL8507258

Cc1ccc(NC(=O)C(C)(C)C)cn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.62
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPSR1 Q6W5P4 2/20 0.51
PAX8 Q06710 1/20 0.51
KLF5 Q13887 1/20 0.51
MAPT P10636 4/20 0.50
ALDH1A1 P00352 3/20 0.50
KCNQ3 O43525 1/20 0.50
KCNQ2 O43526 1/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TP53 P04637 1/20 0.47
SORT1 Q99523 1/20 0.47
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38661078 0.84 KCNQ3 (0.52) L3MBTL1NPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL15075616 0.83 NPSR1 (0.47) L3MBTL1NPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL5648687 0.82 L3MBTL1 (0.62) L3MBTL1NPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL2242286 0.81 NPSR1 (0.57) NPC1RAB9ASMN1; SMN2NPSR1MAPT
SCHEMBL30919458 0.81 NPSR1 (0.57) NPC1RAB9ASMN1; SMN2NPSR1MAPT
SCHEMBL30317019 0.81 L3MBTL1 (0.60) L3MBTL1NPC1RAB9ASMN1; SMN2PAX8
SCHEMBL9148 0.81 L3MBTL1 (0.60) L3MBTL1NPC1RAB9ASMN1; SMN2PAX8
SCHEMBL2611229 0.81 L3MBTL1 (0.60) L3MBTL1NPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL14329107 0.81 L3MBTL1 (0.60) L3MBTL1NPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL21728740 0.80 NPSR1 (0.44) L3MBTL1NPC1RAB9ASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200223854-A1 BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-07-16 US disclosed
EP-3030081-B1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2017-08-02 EP disclosed
US-20160159781-A1 CHEMICAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 US disclosed
US-8952163-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-02-10 US disclosed
US-8802448-B2 Mixed mode ligands PALL CORPORATION (US) 2014-08-12 US disclosed
US-20140142108-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARM INC (US) 2014-05-22 US disclosed
US-8536339-B2 AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity ALLERGAN, INC. (US) 2013-09-17 US disclosed
US-20130030154-A1 MIXED MODE LIGANDS PALL CORPORATION (US) 2013-01-31 US disclosed
US-8263767-B2 AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity ALLERGAN, INC. (US) 2012-09-11 US disclosed
US-20110288301-A1 AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2011-11-24 US disclosed
US-20110282057-A1 AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY ALLERGAN, INC. (US) 2011-11-17 US disclosed
EP-1303490-B1 N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
EP-1035115-B1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2004-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288301-A1 AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY S1PR1, S1PR2, S1PR3 L3MBTL1 3404/4885NPC1 404/4885RAB9A 3232/4885
US-20200223854-A1 BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS ATXN2, ATXN2L, ATXN10 L3MBTL1 2391/4885NPC1 2734/4885RAB9A 776/4885
US-20160159781-A1 CHEMICAL COMPOUNDS DDT, CBR3, CYP1B1 L3MBTL1 1725/4885NPC1 4651/4885RAB9A 3334/4885
US-20130030154-A1 MIXED MODE LIGANDS NCL, NECTIN4, NCLN L3MBTL1 808/4885NPC1 3854/4885RAB9A 3439/4885
US-20110282057-A1 AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY S1PR1, S1PR2, S1PR3 L3MBTL1 3408/4885NPC1 408/4885RAB9A 3304/4885
US-20140142108-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 L3MBTL1 2298/4885NPC1 2903/4885RAB9A 1552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.